These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 18764953)

  • 1. Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions.
    Parente P; Coli A; Massi G; Mangoni A; Fabrizi MM; Bigotti G
    J Exp Clin Cancer Res; 2008 Sep; 27(1):34. PubMed ID: 18764953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases.
    Důra M; Němejcová K; Jakša R; Bártů M; Kodet O; Tichá I; Michálková R; Dundr P
    Pathol Oncol Res; 2019 Jan; 25(1):361-368. PubMed ID: 29128957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
    Piris A; Mihm MC; Hoang MP
    Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
    Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
    J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
    Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
    J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
    Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
    Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
    Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
    Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p15 in a spectrum of spitzoid melanocytic neoplasms.
    Ma SA; O'Day CP; Dentchev T; Takeshita J; Ridky TW; Seykora JT; Chu EY
    J Cutan Pathol; 2019 May; 46(5):310-316. PubMed ID: 30666677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential diagnostic utility of PRAME and p16 immunohistochemistry in melanocytic nevi and malignant melanoma.
    Bahmad HF; Oh KS; Alexis J
    J Cutan Pathol; 2023 Aug; 50(8):763-772. PubMed ID: 37114299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
    Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
    Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma.
    Park SG; Lee JH; Lee WA; Han KM
    Nucl Med Biol; 2012 Nov; 39(8):1167-72. PubMed ID: 22901702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation between Spitz nevi and malignant melanomas by interphase fluorescence in situ hybridization.
    Wettengel GV; Draeger J; Kiesewetter F; Schell H; Neubauer S; Gebhart E
    Int J Oncol; 1999 Jun; 14(6):1177-83. PubMed ID: 10339676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of p-27 (kip1) in nevi and melanomas.
    Morgan MB; Cowper SE
    Am J Dermatopathol; 1999 Apr; 21(2):121-4. PubMed ID: 10218670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
    Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
    Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.